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Abstract
Background: Novel therapies are necessary to improve outcomes for patients with squamous cell
carcinomas (SCC) of the head and neck. Historically, vaccinia virus was administered widely to
humans as a vaccine and led to the eradication of smallpox. We examined the therapeutic effects
of an attenuated, replication-competent vaccinia virus (GLV-1h68) as an oncolytic agent against a
panel of six human head and neck SCC cell lines.
Results: All six cell lines supported viral transgene expression (β-galactosidase, green fluorescent
protein, and luciferase) as early as 6 hours after viral exposure. Efficient transgene expression and
viral replication (>150-fold titer increase over 72 hrs) were observed in four of the cell lines. At a
multiplicity of infection (MOI) of 1, GLV-1h68 was highly cytotoxic to the four cell lines, resulting
in ≥ 90% cytotoxicity over 6 days, and the remaining two cell lines exhibited >45% cytotoxicity.
Even at a very low MOI of 0.01, three cell lines still demonstrated >60% cell death over 6 days. A
single injection of GLV-1h68 (5 × 106 pfu) intratumorally into MSKQLL2 xenografts in mice
exhibited localized intratumoral luciferase activity peaking at days 2–4, with gradual resolution over
10 days and no evidence of spread to normal organs. Treated animals exhibited near-complete
tumor regression over a 24-day period without any observed toxicity, while control animals
demonstrated rapid tumor progression.
Conclusion: These results demonstrate significant oncolytic efficacy by an attenuated vaccinia
virus for infecting and lysing head and neck SCC both in vitro and in vivo, and support its continued
investigation in future clinical trials.
Background
It is estimated that over 35,000 new cases of squamous
cell carcinoma involving the oral cavity or pharynx were
diagnosed in the United States in 2008, and that these
malignancies led to over 7,500 deaths that year [1].
Despite refinements in the application of conventional
cancer therapy modalities including radiation, chemo-
therapy, and surgery, the overall survival of patients with
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advanced head and neck squamous carcinoma remains
limited [2]. Novel therapeutic agents are needed to
improve poor outcomes for patients with head and neck
cancer who fail conventional therapy.
Oncolytic viral therapy is a promising approach to cancer
treatment that relies on the natural ability of viruses to
infect, replicate within, and ultimately lyse a host cell. A
variety of viruses have been demonstrated to exhibit onc-
olytic properties including adenovirus, herpes simplex
virus, Newcastle disease virus, vesicular stomatitis virus,
reovirus, among others [3]. Vaccinia has many favorable
characteristics as an oncolytic virus, including the ability
to infect a wide range of hosts, efficient infection and gene
expression, and potent lytic activity [4]. Vaccinia viral rep-
lication occurs exclusively in the cytoplasm, which elimi-
nates the possibility of chromosomal integration. One of
the most attractive features of vaccinia as a therapeutic
agent is its long and established safety record in its wide-
spread historical use in humans as a vaccine for smallpox.
Interestingly, vaccinia virus appears to naturally possess
an intrinsic ability to selectively target and infect cancer
cells in vivo [5]. The oncolytic activity of a recombinant,
replication-competent vaccinia virus (GLV-1h68) in treat-
ing human thyroid cancer, breast cancer, malignant pleu-
ral mesothelioma, and pancreatic cancer was described
before [6-10]. A GLV-1h68 derivative (GLV-1h99) that
expresses the human nonepinephrine transporter was
recently shown to be useful for both therapy and deep-tis-
sue imaging of tumors [11,12]. In the current study, we
sought to assess the utility of applying GLV-1h68 as a ther-
apeutic agent against human head and neck squamous
cell carcinoma both in vitro and in vivo using a murine
flank tumor model.
Results
In vitro X-gal staining and GFP visualization
X-gal histochemistry of six human HNSCC cell lines dem-
onstrated evidence of infection by GLV-1h68 at 6 hours
after exposure to GLV-1h68 at an MOI of 5 in all of the cell
lines (Figure 1). Furthermore, there was intensely positive
staining by four of the cell lines (MSKQLL2, SCC15,
MSKQLL1, and SCC25) within 24 hours of exposure. The
two other cell lines (MDA1386, MSK922) also demon-
strated positive X-gal staining, although to a lesser degree.
GFP assessment by microscopy showed peak expression at
24 hours and exhibited very similar findings as the X-gal
staining, with the cell lines exhibiting GFP expression in
the same relative order of intensity as demonstrated by the
X-gal staining.
In vitro quantification of β-galactosidase and luciferase 
enzymatic activities
Quantitative assays for β-galactosidase expression by GLV-
1h68 at an MOI of 5 reflected qualitative visual findings
from X-gal staining, with MSKQLL2 showing the highest
expression and MSK922 the lowest expression (Figure 2a).
All of the cell lines demonstrated some degree of suscepti-
bility to infection by GLV-1h68. Luciferase expression
measured by software quantification of acquired photon
emission images demonstrated very similar findings as
the quantitative β-galactosidase assays, with the same rel-
ative order of expression noted (Figure 2b).
Viral replication
Low dose GLV-1h68 at an MOI of 0.1 (2 × 103 pfu) was
added to the cell lines for a three day course to allow for
measurement of viral replication. The four HNSCC cell
lines (MSKQLL2, SCC15, MSKQLL1, SCC25) most sensi-
tive to viral infection as demonstrated by β-galactosidase
and luciferase assays also supported robust viral prolifera-
tion, ranging from a >330-fold increase in GLV-1h68 titer
(SCC15) to a >150-fold increase (SCC25) over the 3-day
period (Figure 2c). In contrast, the less sensitive MSK922
and MDA1386 cell lines demonstrated a ten-fold increase
and an unchanged viral titer, respectively.
Cytotoxicity assays
GLV-1h68 incubated over a 6-day period with each of the
six HNSCC cell lines demonstrated significant cytotoxicity
against all cell lines at an MOI of 0.01, 0.1, and 1 (Figure
3). The relative cytotoxic sensitivities of the six cell lines
reflected their relative susceptibility to GLV-1h68 infec-
tion by β-galactosidase and luciferase assessment. GLV-
1h68 at an MOI of 1 was nearly completely cytotoxic by
day 6 for the four most sensitive cell lines: MSKQLL2,
SCC15, MSKQLL1, and SCC25. Even MDA1386 and
MSK922 showed significant cytotoxicity to GLV-1h68 at
MOI 1, with 47% and 55% viability by day 6, respectively.
The lower MOI curves also reflect this same relative order
of susceptibility. Even at a very low MOI of 0.01,
MSKQLL2, SCC15, and MSKQLL1 demonstrated signifi-
cant cell death by day 6, which reflects exquisite sensitivity
by half of the cell lines treated with GLV-1h68.
In vivo GLV-1h68 gene expression
Luciferase imaging demonstrated increasing activity
remaining localized specifically to the MSKQLL2 flank
tumor after the GLV-1h68 injection, with peak levels
noted at days 2–4 (Figure 4a). There was a subsequent
decline of luciferase activity to day 10. No luciferase activ-
ity was detected in other sites of the animal. At day 3, both
β-galactosidase expression measured by X-gal staining
(Figure 4c) and GFP expression (Figure 4d) appeared
intense, reflecting effective viral gene expression.
Therapy of human SCC xenografts with GLV-1h68 in mice
Established MSKQLL2 flank tumors with a mean starting
volume of 24 mm3 were treated with a single dose of intra-
tumoral GLV-1h68 and the animals were followed for aMolecular Cancer 2009, 8:45 http://www.molecular-cancer.com/content/8/1/45
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period of 24 days. Treated tumors demonstrated progres-
sive tumor volume regression over a three week period,
and by day 24 the mean tumor volume was just 1.3 ± 0.9
mm3 (Figure 5a). Three out of five animals had a complete
regression of tumor, with the other two animals demon-
strating only a tiny 1–2 mm remnant of skin thickening at
the regressed tumor site. In contrast, all of the control
tumors progressively increased in size to a mean volume
of 148 ± 15 mm3 over the same period (p < 0.001, t-test).
Mean body weights remained stable for both control and
GLV-1h68 groups (Figure 5a). There was no morbidity
attributable to GLV-1h68 therapy identified in any ani-
mal. The experiment was concluded at day 24 due to
ulceration of one of the control tumors.
Discussion
Novel therapies are needed to make improvements in out-
comes for patients afflicted with head and neck squamous
cell carcinomas involving the upper aerodigestive tract
[2]. Agents with novel mechanisms of anti-tumoral activ-
ity would be particularly useful for the treatment of recur-
rent cancers that have developed resistance to radiation
therapy or chemotherapy. Oncolytic viral therapy is a new
approach to cancer treatment that harnesses a virus's nat-
Effective early infection by GLV-1h68 of human head and neck squamous cell carcinoma cell lines Figure 1
Effective early infection by GLV-1h68 of human head and neck squamous cell carcinoma cell lines. Six cell lines 
were infected by GLV-1h68 at an MOI of 1 and fixed in 1% glutaraldehyde for X-gal staining, or unfixed cells were visualized 
under a GFP filter. Photomicrographs were taken at 100×. All six cell lines showed progressively increasing marker gene 
expression within 24 hours, demonstrating effective infection at early time points.Molecular Cancer 2009, 8:45 http://www.molecular-cancer.com/content/8/1/45
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ural ability to infect, replicate within, and lyse a host cell
as part of its natural life cycle [3,4].
Interestingly, there is compelling evidence that vaccinia
virus may possess a natural affinity for infecting malig-
nant tumors. Yu et al demonstrated that LIVP strain-
derived vaccinia virus expressing Renilla  luciferase and
GFP was able to specifically infect C6 glioma, MB-49
murine bladder, and MCF-7 mammary neoplasms at 3 to
6 days after intravenous administration in mice [5]. Imag-
ing of GFP expression demonstrated localization of virus
at neoplastic sites measuring as small as 0.5 mm. In con-
trast, intravenous vaccinia administered to non-tumor-
bearing animals only showed weak and occasional uptake
in small skin lesions, without evidence of significant inter-
nal fluorescence localization.
GLV-1h68 is an attenuated, replication-competent, onco-
lytic vaccinia virus. GLV-1h68 has a mutation in the J2R
gene encoding thymidine kinase which may make viral
replication dependent on host cell thymidine kinase [6].
This attribute may create increased selectivity for malig-
nant tumors but attenuate its ability to replicate in normal
tissues. GLV-1h68 also carries an insertional mutation in
hemagglutinin gene and the F14.5L locus. Inactivation of
hemagglutinin is thought to reduce the virulence of vac-
cinia. F14.5L has a unique Not I site in F14.5L makes this
locus suitable for insertion of the luciferase-GFP cassette.
Lin  et al showed that GLV-1h68 injections into estab-
lished anaplastic thyroid tumors in murine flanks resulted
in specific and prolonged luciferase expression within
tumor tissues, while this was absent when GLV-1h68 was
injected into normal tissue sites [8].
Our goal was to explore the potential utility of applying
GLV-1h68 as a therapeutic agent for human head and
neck squamous cell carcinoma. We examined the effects
of GLV-1h68 in treating a panel of six human head and
neck SCC cell lines in vitro. These six cell lines are of
mucosal origin from the upper aerodigestive tract, and are
commonly used to represent this disease. All six cell lines
supported viral transgene expression (β-galactosidase,
green fluorescent protein, luciferase) beginning as early as
6 hours after viral exposure. Highly efficient transgene
expression and viral replication was observed in four of
the six cell lines, suggesting that there are cancer cell fac-
tors that are determinants of permissiveness to vaccinia.
The low dose of GLV-1h68 used in the viral replication
studies was intended to allow assessment of maximal viral
replication, and may have been insufficient to allow for
initial infection of the less sensitive cell lines.
At an MOI of 1, GLV-1h68 was highly cytotoxic to four of
the cell lines, resulting in ≥ 90% cytotoxicity over a 6-day
period. Even at an extremely low MOI of 0.01, three cell
lines still demonstrated > 60% cell death over 6 days.
Therefore, half of SCC cell lines tested exhibited exquisite
sensitivity to GLV-1h68. The other three SCC cell lines
remained susceptible to oncolysis at higher doses of GLV-
1h68, demonstrating that the virus may still exhibit effi-
cacy at higher doses.
We found that markers of early gene expression by GLV-
1h68 correlated well with susceptibility to oncolysis. β-
galactosidase, GFP, and luciferase expression were all
robust for MSKQLL2, SCC15, MSKQLL2, and SCC25;
these were also the same cell lines that were also most sen-
In vitro quantification of gene expression and viral replication  by GLV-1h68 in human head and neck squamous cell carci- noma Figure 2
In vitro quantification of gene expression and viral 
replication by GLV-1h68 in human head and neck 
squamous cell carcinoma. A. Cell lines were infected 
with GLV-1h68 at an MOI of 5, and six hours later quantita-
tive β-galactosidase assays were performed. B. Cell lines 
were infected with GLV-1h68 at an MOI of 1, and 12 hours 
later coelenterazine was added. Bioluminescence was imaged 
with a cooled CCD camera and quantified with software 
analysis. C. Cell lines were exposed to GLV-1h68 at an MOI 
of 0.1 and incubated for 72 hours. Supernatants were col-
lected and viral titers quantified by plaque assays on conflu-
ent CV-1 cells.
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sitive to viral replication and oncolysis. These correlations
suggest that initial viral entry and early gene expression by
GLV-1h68 are important events that may define subse-
quent cytotoxic susceptibility to the virus. Clinically, this
observation also suggests that luciferase imaging to visu-
ally track early viral activity in vivo may potentially have
prognostic utility in predicting later tumor response to the
virus. Bioluminescence imaging allows for the non-inva-
sive detection of viral distribution and viral activity of
GLV-1h68.
A single injection of intratumoral GLV-1h68 (5 × 106 pfu)
in vivo into MSKQLL2 xenografts in mice exhibited local-
ized intratumoral luciferase activity peaking at days 2–4,
with gradual resolution over 10 days. Importantly, there
was no evidence of viral spread to normal organs or non-
tumor sites based on luciferase imaging, demonstrating
tumor-specific viral replication and activity. Treated ani-
mals exhibited essentially complete tumor regression over
a 24-day period without any observed toxicity, while con-
trol animals demonstrated rapid tumor progression
requiring sacrifice by day 24. The lag period between the
earlier resolution of GLV-1h68 luciferase activity and the
later tumor volume regression might, in part, be explained
by the additional time needed for the resorption of
necrotic tumor tissue after effective oncolysis is com-
pleted. No animal treated with GLV-1h68 exhibited any
morbidity attributable to the viral therapy. These results
demonstrate that GLV-1h68 exhibits significant therapeu-
tic efficacy leading to dramatic tumor regression without
observed toxicity when delivered by intratumoral injec-
tion.
A major consideration in the development of a therapy
using replication-competent viruses is the safety of its
application in patients. Most oncolytic viruses such as
adenovirus and herpes simplex virus are natural patho-
gens, and viral attenuation is necessary to make them safe
for clinical use [3]. In contrast, the widespread historical
use of vaccinia as a vaccine for smallpox has convincingly
demonstrated its safety for clinical application in humans.
Toxicities related to vaccinia administration occur in less
than 0.1% of cases, and may be effectively addressed with
immunoglobulin administration [13] and other possible
antivirals such as cidofovir [14] and ST-246 [15]. The rou-
tine administration of vaccinia in the United States ended
in 1972, and smallpox was officially declared eradicated
in 1980. Therefore, the widespread historical clinical use
of vaccinia virus in humans is strong evidence of its likely
safety as a future cancer therapy agent. The additional
genetic attenuation of GLV-1h68 may even further
enhance its safety profile over wild type vaccinia virus.
Our findings support the continued study of GLV-1h68
for treating head and neck squamous cell carcinoma in
future clinical trials.
Conclusion
These results highlight the ability of GLV-1h68 to effec-
tively infect, replicate within, and cause regression of
human head and neck squamous cell carcinoma
GLV-1h68 exhibits significant oncolytic effects in human head and neck squamous cell carcinoma in vitro Figure 3
GLV-1h68 exhibits significant oncolytic effects in human head and neck squamous cell carcinoma in vitro. Six 
cell lines were infected with GLV-1h68 at varying MOIs (0.01, 0.1, 1) and lactate dehydrogenase assays performed for 6 days to 
assess cell viability. Untreated cells were considered 100% viable. The y-axis designates percentage viability, and the x-axis des-
ignates the day post-infection. All six cell lines sustained significant cytotoxicity at an MOI of 1, four cell lines were sensitive at 
an MOI of 0.1, and three cell lines demonstrated an exquisite sensitivity to GLV-1h68 even at a very low MOI of 0.01.Molecular Cancer 2009, 8:45 http://www.molecular-cancer.com/content/8/1/45
Page 6 of 9
(page number not for citation purposes)
xenografts in mice. No treatment related morbidity or
mortality was identified. Vaccinia was historically used
widely as a smallpox vaccine with an excellent safety pro-
file. GLV-1h68 is even further attenuated for safety, while
maintaining potent antitumor activity. These data support
the continued study of GLV-1h68 as an agent to treat
patients with head and neck squamous cell carcinoma in
future clinical trials.
Methods
Virus and cell lines
GLV-1h68 is a recombinant, replication-competent vac-
cinia virus derived from the LIVP strain (Lister strain from
the Institute for Research on Viral Preparations, Moscow).
The construction of GLV-1h68 has been described before
[5]. GLV-1h68 contains four inserted cassettes encoding
Renilla luciferase-green fluorescent protein fusion (RUC-
GFP cassette), a reverse inserted human transferrin recep-
tor (rTfr), β-galactosidase, and β-glucuronidase into the
F14.5L, J2R (thymidine kinase), and A56R (hemaggluti-
nin) loci of the viral genome, respectively.
Six human head and neck squamous cell carcinoma cell
lines were studied: MSKQLL2, SCC15, MSKQLL1, SCC25,
MDA1386, and MSK922. MDA1386 was grown in RPMI
containing 10% FCS and 1% penicillin and streptomycin
GLV-1h68 imaging in vivo shows selective and prolonged virus-mediated luciferase activity in tumors Figure 4
GLV-1h68 imaging in vivo shows selective and prolonged virus-mediated luciferase activity in tumors. A. Estab-
lished MSKQLL2 flank tumors were injected with GLV-1h68 (5 × 106 pfu) and luciferase activity imaged following retro-orbital 
coelenterazine injections over a 10 day period. The late reduction of luciferase activity correlated with tumor size regression. 
B. Quantification of luciferase activity over a 10 day time course using software assessment of emitted photons was performed 
(n = 3 animals). C & D. MSKQLL2 flank tumors were excised 3 days after GLV-1h68 injection and stained for β-galactosidase 
expression (C) or examined under a GFP filter after tumors were exposed surgically (D) for photomicroscopy (100×).Molecular Cancer 2009, 8:45 http://www.molecular-cancer.com/content/8/1/45
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(P&S), all other cell lines were grown in MEM containing
10% FCS and 1% P&S. CV-1 African green monkey kidney
cells used for viral tittering were grown in DMEM contain-
ing 10% FCS and 1% P&S. All cells were grown in a
humidified incubator at 5% CO2 and 37°C.
In vitro X-gal staining and GFP visualization
Cells were seeded in 12 well plates for 6 hours and
exposed to GLV-1h68 at an MOI of 1. At 6, 12, and 24
hours after virus infecton, cells were fixed in 1% glutaral-
dehyde and stained with X-Gal (1 mg/ml) in an iron solu-
tion of 5 mM K4Fe (CN)6, 5 mM K3Fe(CN)6 and 2 mM
MgCl2 at 37°C for 2 hours. Photomicrographs were taken
at 100 ×. At 12 and 24 hours, unfixed cells were imaged
under a microscope with a GFP filter at 100 ×.
In vitro quantification of β-galactosidase activity
β-galactosidase expression was measured using the
Enhanced β-Galactosidase Assay Kit (Gene Therapy Sys-
tems, San Diego, CA). Each cell line was plated in 96-well
plates at 2 × 104 cells per well in 100 μl DMEM with 2%
FCS media for 6 hours. GLV-1h68 in 100 μl media was
added to each well at an MOI of 5. After 6 hours, media
was aspirated and lysis buffer added to each well. Serial
dilutions of β-galactosidase were used to create a standard
reference curve. Substrate was added to each well and
plates read by spectrophotometry (EL321e, Bio-Tek
Instruments, Winooski, VT) at 570 nm. Samples were
assayed in triplicate for each condition and mean values
with standard errors reported.
A single injection of GLV-1h68 results in complete regression of established MSKQLL2 flank tumors in vivo Figure 5
A single injection of GLV-1h68 results in complete regression of established MSKQLL2 flank tumors in vivo. A. 
Established MSKQLL2 flank tumors (n = 5 per group) were treated with a single intratumoral injection of GLV-1h68 (5 × 106 
pfu) and followed. Measured tumor volumes for the GLV-1h68 group demonstrated nearly complete regression, with three 
out of five animals showing complete tumor resolution and the other two demonstrating only a tiny 1–2 mm remnant of skin 
thickening at the regressed tumor site. In contrast, there was significant progression of tumor volume for the control, PBS-
treated group. There was no observed change in animal weight related to viral administration, and no evidence of any toxicity. 
B. A representative animal from each group was photographed at day 24.Molecular Cancer 2009, 8:45 http://www.molecular-cancer.com/content/8/1/45
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In vitro quantification of luciferase activity
For luciferase assessment, cells were plated in 96-well
plates at 1 × 104 cells per well and 6 hours later GLV-1h68
was added at an MOI of 1. 12 hours after infection, 0.25
μg coelenterazine (Biotium, Hayward, CA) in 50 μl PBS
was added to each well for 10 minutes, and emitted pho-
tons were measured for 30 seconds with a cooled CCD
camera (Xenogen IVIS, Xenogen, Alameda, CA). Images
were analyzed by using Living Image® software (Xenogen).
Samples were assessed in triplicate.
Viral plaque assays
To assess viral replication, 2 × 104 cells were seeded per
well in 12-well plates in 1 ml media. After incubation for
6 hours, GLV-1h68 in 100 μl DMEM 2% FCS was added
to each well at an MOI of 0.1 (2 × 103 pfu). Supernatant
from each well was collected at 72 hours and frozen. CV-
1 cells were grown to confluence on 6-well plates. Super-
natant samples were thawed, and serial ten-fold dilutions
incubated on the CV-1 cells for 4 hours. Wells were
washed with media and covered with 1% agarose with
media. After 48 hours of incubation, 2 mL of neutral red
solution (2% by volume) was added and viral plaques
were counted after 24 hours. Samples were assayed in trip-
licate for each condition and mean values with standard
errors reported.
Cytotoxicity assays
Each cell line was plated in 12-well plates. After incuba-
tion for 6 hours, virus in 100 μl DMEM with 2% FCS
media was added to each well at an MOI of 0, 0.01, 0.1
and 1. After day 3, an additional 1 ml of fresh media was
added to remaining wells. At daily intervals cells were
washed with PBS and lysed with Triton X (1.35%, Sigma).
Lactate dehydrogenase (LDH) was measured using a
Cytotox96 kit (Promega, Madison, WI) and measured by
spectrophotometry (EL321e, Bio-Tek Instruments,
Winooski, VT) at 450 nm. Results were expressed as the
percentage of surviving cells determined from comparing
the lactate dehydrogenase of each test sample to untreated
samples considered 100% viable. Samples were assayed in
triplicate for each condition and mean values with stand-
ard errors reported.
In vivo GLV-1h68 gene expression
In vivo experiments were performed under an approved
animal protocol by the Memorial Sloan-Kettering Institu-
tional Animal Care and Use Committee. Six-week-old
male athymic nude mice (National Cancer Institute) were
anesthetized with inhalational methoxyflurane.
MSKQLL2 cells (5 × 106) in 100 μl of PBS were injected
into the subcutaneous flanks. Established MSKQLL2 flank
tumors were injected with GLV-1h68 (5 × 106 pfu) in 50
μl PBS. For luciferase assessment, 2.5 μg of coelenterazine
(Biotium) in 95 μl PBS was injected via the retro-orbital
sinus at varying times. Luciferase activity was detected
with a cooled CCD camera (Xenogen IVIS). Emitted pho-
tons were measured for 60 seconds. Images were analyzed
using Living Image® software (Xenogen).
For X-gal staining, at day 3 animals were sacrificed and
flank tumors excised, frozen in Tissue Tek solution and
sectioned (8 μm). Slides were fixed with 1% glutaralde-
hyde and stained with X-Gal (1 mg/ml) in an iron solu-
tion of 5 mM K4Fe (CN)6, 5 mM K3Fe(CN)6 and 2 mM
MgCl2 at 37°C for 2 hours. Slides were counterstained
with nuclear fast red. For GFP assessment, animals were
sacrificed at day 3, tumors exposed surgically, and photog-
raphy performed under a stereoscope (Leica MZFL3) with
a GFP filter.
Therapy of human SCC xenografts with GLV-1h68 in mice
Animals with established MSKQLL2 flank tumors were
distributed into two experimental groups (n = 5 per
group) with similar starting tumor volumes. Flank tumors
were treated with intratumoral injections of a single dose
of GLV-1h68 (5 × 106 pfu) in 50 μl PBS, or 50 μl PBS alone
as control. Tumor dimensions were serially measured
with calipers and volumes calculated by the formula: vol-
ume = length × width2 × 0.4. Body weights were measured
serially. Photographs of representative animals were taken
at day 24. Animals were sacrificed by CO2 inhalation.
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